Mission, vision and objectives
Design and development of biomarker-based assays for early cancer diagnosis and monoclonal antibodies for targeted therapy.
Consolidating the use of auto-antibodies as biomarkers for early detection of cancer. Autoantibodies, generated by human body against neoproteins related to the tumor, appear at detectable levels in patient’s blood early and at high concetrations when compared to another type of biomarkers like proteins, RNA,DNA, metabolites,..., thus allowing earlier diagnosis even before symptoms are present and also before other biomarkers can be measured. The extended long half life and good stability in blood of autoantibodies makes them more robust as early diagnostic tools.